Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10595
Peer-review started: July 28, 2021
First decision: August 19, 2021
Revised: August 28, 2021
Accepted: October 14, 2021
Article in press: October 14, 2021
Published online: December 6, 2021
Compared to remimazolam, remimazolam benzenesulfonate has a faster effect, is more quickly metabolized, produces inactive metabolites and has weak drug interactions. Remimazolam benzenesulfonate has good effectiveness and safety for diagnostic and operational sedation.
This study investigated the clinical value of remimazolam benzenesulfonate in cardiac surgery patients under general anesthesia.
In order to explore the clinical value of remimazolam benzenesulfonate under general anesthesia in patients undergoing cardiac surgery.
In total, 80 patients who underwent surgery were included in the study. Using a random number table, patients were divided into two anesthesia induction groups of 40 patients each: Remimazolam and propofol. Hemodynamic parameters, inflammatory stress response indices, respiratory function indices, perioperative indices and adverse reactions in the two groups were monitored over time for comparison.
At pre-anesthesia induction, the remimazolam and propofol groups did not differ regarding heart rate, mean arterial pressure, cardiac index or volume per wave index. After endotracheal intubation and when the sternum was cut off, mean arterial pressure and volume per wave index were significantly higher in the remimazolam group than in the propofol group. After endotracheal intubation, the oxygenation index and the respiratory index did not differ between the groups. After endotracheal intubation and when the sternum was cut off, the oxygenation index values were significantly higher in the remimazolam group than in the propofol group. Serum interleukin-6 and tumor necrosis factor-α levels 12 h after surgery were significantly higher than before surgery in both groups.
The results suggest that compared with propofol, remimazolam benzenesulfonate benefited cardiac surgery patients under general anesthesia by reducing hemodynamic fluctuations.
Remimazolam benzenesulfonate can affect surgical stress response and respiratory function, thereby reducing adverse reactions related to anesthesia and has greater clinical promotion value.